Suppression of oncogenic signaling by tumor suppressor REIC/Dkk-3

2016 Fiscal Year Final Research Report

• Project/Area Number: 26293352
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: Kumon Hiromi 岡山大学, 医歯(薬)学総合研究科, 特命教授 (30144760)
• Co-Investigator(Kenkyū-buntansha): 高本 篤 岡山大学, 大学病院, 助教 (30716816) ; 江原 伸 岡山大学, 大学病院, 講師 (70379741) ; 阪口 政清 岡山大学, 医歯(薬)学総合研究科, 准教授 (70379840) ; 佐々木 克己 岡山大学, 大学病院, 助教 (80467745)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 遺伝子治療 / 癌増殖抑制 / REIC/Dkk-3

Outline of Final Research Achievements

Reduced expression in immortalized cells (REIC)/Dickkopf (Dkk)-3 is a tumor suppressor gene and has been studied with respect to the application of cancer gene therapy. Our previous studies demonstrated that adenovirus-mediated REIC/Dkk-3 overexpression induced significant apoptosis in the treated tumor sites. In this study, we further investigated the mechanisms underlying the antitumor therapeutic effects of Ad-REIC and clarified that the treatment inhibits cancer progression via modification of several oncogenic signaling.

Free Research Field

泌尿器科学、遺伝子治療学